Trump Signs Executive Order on Psychedelics, Boosting Compass Pathways Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy CMPS?
Source: Yahoo Finance
- Stock Surge: Compass Pathways' stock surged significantly after President Trump signed an executive order related to psychedelic drugs, reflecting market optimism regarding the company's future, particularly in mental health applications.
- Policy Impact: The executive order may create a more favorable regulatory environment for the research and development of psychedelics, potentially accelerating Compass Pathways' innovation in new therapies and enhancing its competitive position.
- Investor Confidence: Increased attention on psychedelics has drawn more investors to the sector, benefiting Compass Pathways as it is expected to attract more capital to support its R&D projects.
- Industry Outlook: As the therapeutic potential of psychedelics for mental health issues gains recognition, Compass Pathways is poised to lead in this emerging market, driving long-term growth for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CMPS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CMPS
Wall Street analysts forecast CMPS stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 6.660
Low
8.00
Averages
18.43
High
40.00
Current: 6.660
Low
8.00
Averages
18.43
High
40.00
About CMPS
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Compass Pathways Applauds White House Executive Order on Mental Health
- Policy Support: Compass Pathways commends the White House's Executive Order aimed at accelerating medical treatments for serious mental illnesses, highlighting that this policy addresses the urgent mental health crisis faced by millions of Americans and could expedite FDA approval for psychedelic treatments, thereby enhancing patient access to care.
- Clinical Trial Results: COMP360 synthetic psilocybin has achieved significant results in two phase 3 trials for treatment-resistant depression, with data indicating effects observable within one day after just one or two doses, and durability lasting at least six months, showcasing its unique clinical value in mental health treatment.
- Market Potential: With approximately four million Americans suffering from treatment-resistant depression and 13 million from PTSD, Compass is actively conducting related clinical programs, and the new policy is expected to accelerate the regulatory approval process for COMP360, addressing the urgent treatment needs of patients.
- Strategic Development: COMP360 has received Breakthrough Therapy designation from the FDA and Innovative Licensing in the UK, indicating its potential in mental health treatment; Compass plans to collaborate closely with the FDA to advance its commercialization efforts, aiming to provide effective treatment options to a broader patient population.
See More
Trump Signs Executive Order on Psychedelics, Boosting Compass Pathways Stock
- Stock Surge: Compass Pathways' stock surged significantly after President Trump signed an executive order related to psychedelic drugs, reflecting market optimism regarding the company's future, particularly in mental health applications.
- Policy Impact: The executive order may create a more favorable regulatory environment for the research and development of psychedelics, potentially accelerating Compass Pathways' innovation in new therapies and enhancing its competitive position.
- Investor Confidence: Increased attention on psychedelics has drawn more investors to the sector, benefiting Compass Pathways as it is expected to attract more capital to support its R&D projects.
- Industry Outlook: As the therapeutic potential of psychedelics for mental health issues gains recognition, Compass Pathways is poised to lead in this emerging market, driving long-term growth for the company.
See More
Trump Signs Order to Accelerate Psychedelic Research and Access
- Market Reaction: Following President Trump's executive order to accelerate psychedelic research, premarket trading saw Compass Pathways (CMPS) surge 25%, AtaiBeckley (ATAI) jump 22%, and Definium Therapeutics (DFTX) climb 20%, indicating strong market enthusiasm for the renewed policy support.
- Valuation Signal Analysis: Among psychedelic stocks, Cybin (HELP) stands out with an A grade valuation signal, suggesting it is the most attractively priced relative to fundamentals, while GH Research (GHRS) and Compass Pathways (CMPS) received C- and D+ grades, indicating a premium pricing situation.
- Investor Focus: Despite the bullish market sentiment, Definium Therapeutics (DFTX) and AtaiBeckley (ATAI) both carry D- grades, signaling that these stocks are trading at significant premiums to their current fundamentals, prompting investors to exercise caution.
- Industry Outlook: With Trump's order accelerating PTSD research, the potential market for psychedelics is expanding, which could present new growth opportunities for related companies, particularly in the treatment of serious mental illnesses.
See More
Premarket Moves: Airlines Under Pressure, Tech Stocks Surge
- Airlines Decline: Airlines such as American Airlines, Delta Air Lines, and United Airlines saw their stocks drop over 2% as investors worry that renewed U.S.-Iran tensions will elevate energy prices, leading to reduced consumer travel.
- Tech Stocks Surge: Shares of Marvell Technology and Broadcom jumped more than 7% following reports of talks with Google to develop new AI chips, although Broadcom's stock fell nearly 1.5% on the news.
- TopBuild Acquisition: TopBuild's stock surged over 17% after QXO announced its acquisition for $17 billion, which is expected to create a higher-margin business and be immediately accretive to earnings.
- AST SpaceMobile Drop: AST SpaceMobile's shares fell 15% after a satellite was launched into the wrong orbit, although the company expects to recover costs through insurance and plans to conduct monthly orbital launches starting in 2026.
See More
Trump Signs Executive Order to Accelerate Psychedelic Drug Reviews
- Market Reaction: Following President Trump's executive order, shares of psychedelic drug developers surged in premarket trading, with Atai Life Sciences up 21%, Definium Therapeutics rising 15%, and Compass Pathways climbing 26%, indicating strong market confidence in the psychedelic sector.
- Executive Order Details: The order directs the FDA to expedite reviews of psychedelic drugs, particularly ibogaine for treating PTSD, depression, and addiction, potentially reducing review times from 6-10 months to just 1-2 months, significantly enhancing the industry's outlook.
- Government Funding Support: Trump announced a $50 million allocation for federal research into ibogaine, providing crucial financial backing for the development of psychedelic drugs and further propelling industry growth.
- Regulatory Risk Mitigation: Analysts noted that the executive order represents a government endorsement of psychedelics, reducing regulatory risks and potentially facilitating legislative efforts to expand access to psychedelic therapies, reflecting bipartisan interest and support in this field.
See More
Compass Pathways CEO to Join Psychedelics Forum Panel
- CEO Participation: Compass Pathways CEO Kabir Nath will participate in a panel titled 'Clinical Risk, Regulatory Reality and the Path to Scale' at the Needham Virtual Psychedelics Forum on April 27, 2026, highlighting the company's leadership in mental health innovation.
- Webcast Availability: The event will be accessible via a live audio webcast on the Compass website's Investors section, with a replay available for 30 days post-event, ensuring that investors and the public can access critical information.
- Innovative Treatment: The investigational COMP360 synthetic psilocybin treatment has received Breakthrough Therapy designation from the FDA and Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression, indicating its potential as a first-in-class therapy.
- Global Presence: With headquarters in London and an office in New York, Compass Pathways demonstrates its commitment to advancing mental health innovation on a global scale, aiming to assist patients who are unresponsive to existing treatments.
See More
Compass Pathways Applauds White House Executive Order on Mental Health
- Policy Support: Compass Pathways commends the White House's Executive Order aimed at accelerating medical treatments for serious mental illnesses, highlighting that this policy addresses the urgent mental health crisis faced by millions of Americans and could expedite FDA approval for psychedelic treatments, thereby enhancing patient access to care.
- Clinical Trial Results: COMP360 synthetic psilocybin has achieved significant results in two phase 3 trials for treatment-resistant depression, with data indicating effects observable within one day after just one or two doses, and durability lasting at least six months, showcasing its unique clinical value in mental health treatment.
- Market Potential: With approximately four million Americans suffering from treatment-resistant depression and 13 million from PTSD, Compass is actively conducting related clinical programs, and the new policy is expected to accelerate the regulatory approval process for COMP360, addressing the urgent treatment needs of patients.
- Strategic Development: COMP360 has received Breakthrough Therapy designation from the FDA and Innovative Licensing in the UK, indicating its potential in mental health treatment; Compass plans to collaborate closely with the FDA to advance its commercialization efforts, aiming to provide effective treatment options to a broader patient population.
See More
Trump Signs Executive Order on Psychedelics, Boosting Compass Pathways Stock
- Stock Surge: Compass Pathways' stock surged significantly after President Trump signed an executive order related to psychedelic drugs, reflecting market optimism regarding the company's future, particularly in mental health applications.
- Policy Impact: The executive order may create a more favorable regulatory environment for the research and development of psychedelics, potentially accelerating Compass Pathways' innovation in new therapies and enhancing its competitive position.
- Investor Confidence: Increased attention on psychedelics has drawn more investors to the sector, benefiting Compass Pathways as it is expected to attract more capital to support its R&D projects.
- Industry Outlook: As the therapeutic potential of psychedelics for mental health issues gains recognition, Compass Pathways is poised to lead in this emerging market, driving long-term growth for the company.
See More
Trump Signs Order to Accelerate Psychedelic Research and Access
- Market Reaction: Following President Trump's executive order to accelerate psychedelic research, premarket trading saw Compass Pathways (CMPS) surge 25%, AtaiBeckley (ATAI) jump 22%, and Definium Therapeutics (DFTX) climb 20%, indicating strong market enthusiasm for the renewed policy support.
- Valuation Signal Analysis: Among psychedelic stocks, Cybin (HELP) stands out with an A grade valuation signal, suggesting it is the most attractively priced relative to fundamentals, while GH Research (GHRS) and Compass Pathways (CMPS) received C- and D+ grades, indicating a premium pricing situation.
- Investor Focus: Despite the bullish market sentiment, Definium Therapeutics (DFTX) and AtaiBeckley (ATAI) both carry D- grades, signaling that these stocks are trading at significant premiums to their current fundamentals, prompting investors to exercise caution.
- Industry Outlook: With Trump's order accelerating PTSD research, the potential market for psychedelics is expanding, which could present new growth opportunities for related companies, particularly in the treatment of serious mental illnesses.
See More
Premarket Moves: Airlines Under Pressure, Tech Stocks Surge
- Airlines Decline: Airlines such as American Airlines, Delta Air Lines, and United Airlines saw their stocks drop over 2% as investors worry that renewed U.S.-Iran tensions will elevate energy prices, leading to reduced consumer travel.
- Tech Stocks Surge: Shares of Marvell Technology and Broadcom jumped more than 7% following reports of talks with Google to develop new AI chips, although Broadcom's stock fell nearly 1.5% on the news.
- TopBuild Acquisition: TopBuild's stock surged over 17% after QXO announced its acquisition for $17 billion, which is expected to create a higher-margin business and be immediately accretive to earnings.
- AST SpaceMobile Drop: AST SpaceMobile's shares fell 15% after a satellite was launched into the wrong orbit, although the company expects to recover costs through insurance and plans to conduct monthly orbital launches starting in 2026.
See More
Trump Signs Executive Order to Accelerate Psychedelic Drug Reviews
- Market Reaction: Following President Trump's executive order, shares of psychedelic drug developers surged in premarket trading, with Atai Life Sciences up 21%, Definium Therapeutics rising 15%, and Compass Pathways climbing 26%, indicating strong market confidence in the psychedelic sector.
- Executive Order Details: The order directs the FDA to expedite reviews of psychedelic drugs, particularly ibogaine for treating PTSD, depression, and addiction, potentially reducing review times from 6-10 months to just 1-2 months, significantly enhancing the industry's outlook.
- Government Funding Support: Trump announced a $50 million allocation for federal research into ibogaine, providing crucial financial backing for the development of psychedelic drugs and further propelling industry growth.
- Regulatory Risk Mitigation: Analysts noted that the executive order represents a government endorsement of psychedelics, reducing regulatory risks and potentially facilitating legislative efforts to expand access to psychedelic therapies, reflecting bipartisan interest and support in this field.
See More
Compass Pathways CEO to Join Psychedelics Forum Panel
- CEO Participation: Compass Pathways CEO Kabir Nath will participate in a panel titled 'Clinical Risk, Regulatory Reality and the Path to Scale' at the Needham Virtual Psychedelics Forum on April 27, 2026, highlighting the company's leadership in mental health innovation.
- Webcast Availability: The event will be accessible via a live audio webcast on the Compass website's Investors section, with a replay available for 30 days post-event, ensuring that investors and the public can access critical information.
- Innovative Treatment: The investigational COMP360 synthetic psilocybin treatment has received Breakthrough Therapy designation from the FDA and Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression, indicating its potential as a first-in-class therapy.
- Global Presence: With headquarters in London and an office in New York, Compass Pathways demonstrates its commitment to advancing mental health innovation on a global scale, aiming to assist patients who are unresponsive to existing treatments.
See More
